French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). | French ...

The first clinical program to go over involves the use of ImmunityBio's CAR-NK cell therapy CD19 t-haNK, which is being tested in the ongoing phase 1 QUILT 106 study. As I alluded to above ...

NK cell therapy is gaining momentum as a promising solution to unmet medical needs in cancer treatment, offering safer, targeted options for patients unresponsive to traditional therapies. Increased R ...

Artiva Biotherapeutics specializes in advancing a novel NK cell therapy platform targeting autoimmune diseases. The company's approach utilizes unengineered NK cells derived from cord blood ...

Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that the first patients have been dosed in an initial trial studying the potential of the company’s CAR-NK cell therapy ...

Researchers from Naya Biosciences Inc. and collaborators presented preclinical data on NY-303, a natural killer (NK) cell engager bispecific antibody targeting both GPC3 and NKp46. NKp46 is a cell ...

Artiva Biotherapeutics, Inc. (ARTV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today.

Our lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in an ongoing Phase ...

Artiva Biotherapeutics specializes in advancing a novel NK cell therapy platform targeting autoimmune diseases. The company's approach utilizes unengineered NK cells derived from cord blood, combined ...